Microcap Ledger Anika Therapeutics, Inc. $ANIK
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Surgical & Medical Instruments & Apparatus
- Headquarters
- Bedford, MA
- Fiscal year end
- December 31
- Shares outstanding
- 13,382,966 [10-Q 2026-07-29]
What the company doesAI summary of filing
Anika Therapeutics develops and sells injectable and orthopedic regenerative medical products for treating osteoarthritis and tissue repair. The company generates revenue through two channels: the OEM Channel, where it manufactures products for distribution partners (primarily J&J MedTech, representing 50% of 2025 revenue), and the Commercial Channel, where it directly sells products internationally and in the U.S. The company had revenue of $112.8 million in 2025 and recorded a net loss of $10.9 million, making it a revenue-generating but currently loss-generating business. Anika continues investing in clinical development, particularly for Cingal, its next-generation osteoarthritis pain product currently approved outside the United States, and Integrity, an arthroscopic patch system launched commercially in the U.S. [10-K 2026-03-03]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $62.22M | −$1.75M | −$5.53M | $38.41M | [10-Q 2026-07-29] |
| FY ended Dec 2025 | $112.82M | −$11.00M | $11.19M | $57.48M | [10-K 2026-03-03] |
| FY ended Dec 2024 | $119.91M | −$56.00M | $5.40M | $55.63M | [10-K 2026-03-03] |
- Quarterly cash burn
- −$2.77M
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-28 | 14,645,596 | [10-Q 2024-11-04] |
| 2025-03-06 | 14,175,994 | [10-K 2025-03-17] |
| 2025-04-30 | 14,341,423 | [10-Q 2025-05-09] |
| 2025-07-23 | 14,418,090 | [10-Q 2025-07-30] |
| 2025-10-29 | 14,421,219 | [10-Q 2025-11-05] |
| 2026-02-20 | 13,400,751 | [10-K 2026-03-03] |
| 2026-04-21 | 13,305,624 | [10-Q 2026-04-30] |
| 2026-07-24 | 13,382,966 | [10-Q 2026-07-29] |
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-04 | Fischetti Gary P | buy | 1,000 | $20.32 | [4 2026-08-05] |
| 2026-08-03 | Fischetti Gary P | buy | 1,000 | $20.75 | [4 2026-08-05] |
| 2026-06-18 | Fischetti Gary P | grant | 10,402 | — | [4 2026-06-23] |
| 2026-06-18 | Henneman John B Iii | grant | 10,402 | — | [4 2026-06-23] |
| 2026-06-18 | Richard Stephen | grant | 10,402 | — | [4 2026-06-23] |
| 2026-06-18 | Capper Joseph H | grant | 10,402 | — | [4 2026-06-23] |
| 2026-06-18 | Conley Sheryl L | grant | 10,402 | — | [4 2026-06-23] |
| 2026-06-03 | Griffin Stephen D. | exercise | 12,840 | — | [4 2026-06-05] |
| 2026-06-03 | Griffin Stephen D. | other | 3,769 | $14.41 | [4 2026-06-05] |
| 2026-05-01 | Henneman John B Iii | buy | 5,000 | $14.66 | [4 2026-05-04] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-07-31 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-29 | 10-Q | Quarterly report |
| 2026-07-29 | 8-K | Results of operations |
| 2026-07-17 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-14 | 8-K | Material agreement entered; New financial obligation |
| 2026-06-23 | 8-K | Director or officer change; Shareholder vote results |
| 2026-04-30 | 10-Q | Quarterly report |
| 2026-04-29 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-04-29 | 8-K | Results of operations; Director or officer change |
| 2026-04-28 | DEF 14A | Proxy statement |
| 2026-03-26 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-03-03 | 10-K | Annual report |
Alerts for $ANIK
Email me when Anika Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.